Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.
INTRODUCTION
Oral infections including dental caries, periodontitis and periimplantitis are among the most common diseases worldwide (Belibasakis and Mylonakis 2015; El Kholy, Genco and Van Dyke 2015) . It is well known that bacterial biofilms play a major role in the pathogenesis of these infections by forming a protective barrier against antibacterial agents and host immune defenses (Donlan and Costerton 2002; Saini, Saini and Sharma 2011) .
The membrane-acting antiseptic chlorhexidine is often used in the management of oral infections (Prathapachandran and Suresh 2012; van Winkelhoff 2012; Matesanz-Pérez et al. 2013 ). However, long-term use of chlorhexidine can lead to side effects such as oral mucosa irritation, tooth staining and dental calculus formation (Van Strydonck et al. 2012) . Furthermore, extensive use of antibiotics in the management of oral infections can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment (Rams, Degener and van Winkelhoff 2014a, b) . Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections.
De novo development of new antibacterial agents is a slow and expensive process (Fischbach and Walsh 2009) . In recent years, repurposing of approved drugs has increasingly been applied as an alternative strategy to uncover new antibiotics (Rangel-Vega et al. 2015) . This strategy has some advantages over de novo drug discovery, including reduced development costs and fast drug development processes, due to the availability of previously collected data such as toxicological and pharmacological properties (Ashburn and Thor 2004; Chong and Sullivan 2007; Rangel-Vega et al. 2015) .
In the quest for new antibacterial compounds, we conducted a screening of a drug-repositioning library (NIH Clinical Collection) searching for antibacterial compounds that show activity against the anaerobic bacterium Porphyromonas gingivalis, a major pathogen in the development of oral diseases such as periodontitis and peri-implantitis (van Winkelhoff et al. 2000; Smeets et al. 2014) . This led to the selection of three novel compounds that reduced bacterial growth: zafirlukast, toremifene citrate and N-(4-hydroxyphenyl)-arachidonylamide (AM404). The antibacterial activity of zafirlukast, an antiasthma drug that has been approved in Europe and in the USA (Dekhuijzen and Koopmans 2002) , was further characterized in this study. The knowledge gained from this study will be useful to evaluate the clinical potential of zafirlukast for the management of oral infections.
MATERIAL AND METHODS

Bacterial strains and chemicals
The strains Porphyromonas gingivalis ATCC 33277, Streptococcus mutans ATCC 25175, Prevotella intermedia ATCC 49046, Fusobacterium nucleatum ATCC 49256, Aggregatibacter actinomycetemcomitans ATCC 43718, Staphylococcus aureus SH1000 (O'Neill 2010), Staphylococcus epidermidis CH (Costerston, Marrie and Cheng 1985) , Escherichia coli TG1 (Carter, Bedouelle and Winter 1985) , Pseudomonas aeruginosa (Lee et al. 2006) and Salmonella enterica serovar Typhimurium SL1344 (Hoiseth and Stocker 1981) were used in this study. S. mutans, S. aureus, S. epidermidis, E. coli, P. aeruginosa and S. Typhimurium were grown routinely on solid trypticase soy broth (TSB, Becton-Dickinson Benelux nv, Erembodegem-Dorp, Belgium) containing 1.5% agar at 37
• C. P.
gingivalis, P. intermedia, F. nucleatum and A. actinomycetemcomitans were routinely grown on 5% horse blood agar supplemented with hemin (5 μg/ml) and menadione (1 μg/ml) at 37
• C under anaerobic conditions (90% N 2 , 5% H 2 and 5% CO 2 ) using an Anoxomat AN2OP system (Mart Microbiology, Drachten, the Netherlands). Liquid cultures of all strains were grown in TSB.
The drug-repositioning library (NIH Clinical Collection) was supplied by the NIH (http://nihsmr.evotec.com/evotec/) in 96-well plates. Zafirlukast was purchased from Sigma-Aldrich (Machelen, Belgium) and stock solutions of 10 mM were prepared in dimethyl sulfoxide (DMSO).
Screening of a drug-repositioning library
A drug-repositioning library consisting of 727 compounds was screened to identify novel compounds that potentiate the activity of chlorhexidine. Therefore, exponential-phase cells of P. gingivalis were cultured in the wells of 96-well plates in the presence of a subinhibitory concentration of chlorhexidine, namely 0.8 μM (1/8 of the minimum inhibitory concentration (MIC)) and the compounds at a concentration of 10 μM. The total volume in each well was 200 μl. Cells treated with 1× the MIC of chlorhexidine (6.4 μM) were included as a positive control, while cells treated with 1/8× the MIC of chlorhexidine served as a negative control. After 48 h of growth at 37
• C, the OD 595 of each well was measured using a Synergy MX multimode reader (Biotek, Winooski, VT, USA). Those measured OD values were indicative for bacterial growth. All compounds were tested in three biological replicates. Compounds that caused >90% growth inhibition in the presence of 0.8 μM chlorhexidine were selected for further examination. A flowchart of the screening process is given in Fig. S1 (Supporting Information).
Fractional inhibitory concentration index
Synergism between chlorhexidine and zafirlukast was determined by calculating the fractional inhibitory concentration index (FICI) as described previously (Delattin et al. 2014) . The FICI was calculated by the formula FICI = (MIC chlorhexidine, combination / MIC chlorhexidine, alone ) + (MIC zafirlukast, combination / MIC zafirlukast, alone ). A FICI < 0.5 is indicative of synergy, a FICI between 0.5 and 4 is indicative of no interaction and a FICI > 4 is indicative of antagonism.
Minimum inhibitory concentration
MIC assays were performed in TSB medium as previously described . The MIC was interpreted as the lowest antibiotic concentration that completely inhibits bacterial growth.
Inhibition of biofilm formation on polystyrene
To assess biofilm inhibitory activity, P. gingivalis and Staphylococcal biofilms were grown in the presence of zafirlukast as previously described (Liebens, Gerits and Knapen 2014) , with the following alterations: TSB was used as growth medium, overnight cultures of Staphylococcus species were diluted 1/200 in fresh medium and S. epidermidis biofilms were grown in microtiter plates. For S. mutans, overnight cultures were diluted 1/200 in brain-heart infusion medium (Becton-Dickinson Benelux nv, Erembodegem-Dorp, Belgium) supplemented with 3% sucrose and biofilms were grown for 24 h at 37 • C. Biofilm formation was determined using crystal violet staining (Janssens et al. 2008) . The lowest concentration of zafirlukast required to inhibit biofilm formation was defined as the minimum biofilm inhibitory concentration (MBIC).
Eradication of biofilms formed on polystyrene
To examine the potential of zafirlukast to eradicate existing biofilms, biofilms were grown as described above, and subsequently treated with fresh medium containing zafirlukast. After another 24 h of incubation, the viability of the biofilms was determined using cell titre blue as previously described (Delattin et al. 2014) , with the exception that in case of P. gingivalis and Staphylococcus measurements were performed after 24 h instead of 1 h. The minimum biofilm reduction concentration (MBRC) was defined as the lowest concentration of zafirlukast that results in complete eradication of the biofilm.
Inhibition of biofilm formation on titanium disks
To investigate the ability of zafirlukast to inhibit biofilm formation of P. gingivalis and S. mutans on titanium, round titanium disks (commercially pure titanium, grade 2; height: 2 mm, width: 0.5 cm) were used. The disks were placed in 96-well plates. Subsequently, overnight cultures of P. gingivalis and S. mutants were diluted 1/10 in TSB and 1/200 in BHI supplemented with 3% sucrose (Junka et al. 2015) , respectively, and 200 μl of the cell suspensions containing 0-100 μM zafirlukast were added to the wells containing the disks. The disks were incubated for 24 h (S. mutans) or 72 h (P. gingivalis) under static conditions. Next, adherent bacteria were dissociated from the disks by sonication and vortexing, and were quantified by counting CFUs as described previously (Gerits et al. 2016a ).
Eradication of biofilms formed on titanium disks
To examine the effects of zafirlukast on existing biofilms, biofilms of P. gingivalis and S. mutans were established on titanium disks as described above. After washing with PBS, 200 μl of fresh medium containing 0-100 μM zafirlukast was added to the wells of the disks. Next, the disks were incubated at 37
• C for an additional 24 h. Cell growth was determined by CFU counting, as described above.
Determination of the viability of biofilms formed on titanium disks
The BacLight LIVE/DEAD bacterial viability staining kit (Molecular Probes, Invitrogen, Carlsbad, CA, USA) was used to microscopically evaluate the viability of the biofilms formed on titanium disks. After incubation, the disks were washed with 1× PBS and were transferred to a LIVE/DEAD staining solution containing SYTO 9 and propidium iodide (PI) (prepared according to the manufacturer's instructions). After 10 min of incubation at room temperature in the dark, the disks were washed again in 1× PBS and were mounted on a coverslip for imaging. The stained biofilm cells were visualized under a Zeiss Axio imager Z1 fluorescence microscope equipped with a EC Plan-Neofluar 20× objective using the SYTO 9 (λ ex = 483 nm; λ em = 500 nm) and PI (λ ex = 305 nm; λ em = 617 nm) channels.
Cytotoxicity assay
Cytotoxicity of zafirlukast was evaluated by assessing growth inhibition of MG63 osteoblast-like cells (obtained from American Type Culture Collection CRL-1427; LGC Standards, Molsheim, France) by DNA quantification, as described previously (Delattin et al. 2014) . For one of the two experiments, cell viability was confirmed using the LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells (Life Technologies Europe BV, Invitrogen Division, Gent, Belgium) prior to adding the lysis buffer. The live and dead cells were visualized with an inverted fluorescence microscope (Olympus CKX41, Tokyo, Japan) using a reflected fluorescence system mounted on CKX41 with 120 W metal halide lamp with iris diaphragm (10× magnification).
Statistical analysis and reproducibility of the results
Data were analyzed for statistical significance using one-way ANOVA with Dunnett's multiple comparison test. A P-value of < 0.05 was considered to be statistically significant. All bacterial assays were independently repeated at least three times. The experiment using osteoblast-type cells was performed in duplicate.
RESULTS AND DISCUSSION
Screening of a drug-repositioning library against Porphyromonas gingivalis
A screening of a repositioning library was initiated to identify novel compounds that could potentiate the growth-inhibiting activity of subMIC levels of chlorhexidine (0.8 μM) against P. gingivalis. We hypothesized that the use of these potentiators would result in chlorhexidine applications at lower concentrations, thus potentially avoiding unwanted side effects. A total of 727 compounds were screened three times, leading to the identification of 31 compounds that caused >90% growth inhibition (Table S1 , Supporting Information). These compounds included several known antibiotics such as dicloxacillin sodium salt, cefotaxime sodium salt, ampicillin sodium salt and piperacillin sodium salt, demonstrating the validity of our screening method. Next, newly identified antibacterial compounds were ordered from an independent supplier and their activity against P. gingivalis was reassessed. This led to the selection of three novel compounds that showed the most potent activity against P. gingivalis: zafirlukast, toremifene citrate and N-(4-hydroxyphenyl)-arachidonylamide (AM404). A flowchart of the screening process is given in Fig. S1 . Zafirlukast, a medicine used in the treatment of asthma (Dekhuijzen and Koopmans 2002) , was characterized further in this study. Currently, follow-up studies to further characterize the antibacterial activities of toremifene citrate (Gerits et al. 2016b) and N-(4-hydroxyphenyl)-arachidonylamide are being conducted.
To investigate synergy between chlorhexidine and zafirlukast, FICI values were calculated. No synergistic interaction was found between chlorhexidine and the compound (FICI ranging from 1 to 2), suggesting that the compound has antibacterial activity on its own.
Antibacterial activity of zafirlukast
Next, the broad-spectrum antibacterial activity of zafirlukast was evaluated against different oral (Table 1) and non-oral (Table S2 , Supporting Information) bacterial pathogens by determining MIC values. Zafirlukast showed antibacterial and antibiofilm activity against all tested Gram-positive pathogens, including the cariogenic pathogen Streptococcus mutans, but showed no significant activity against Gram-negative bacteria, with the exception of the oral pathogen P. gingivalis. It is known that lipopolysaccharides (LPS) present in the outer membrane of oral Gram-negative bacteria such as P. gingivalis are structurally different from those of Escherichia coli. For example, P. gingivalis is known to produce a very complex LPS containing highly heterogeneous lipid A structures (Jain and Darveau 2011) . It is possible that differences in membrane composition between Gram-negative bacteria explain the observed differences in sensitivity, as more robust membranes may serve as a barrier for diffusion of the compound to the cytoplasm (Nikaido 1985) . Other resistance mechanisms may include the presence of efflux systems, target-inactivating enzymes or antibiotic-inactivating enzymes (Lewis 2013) . Furthermore, additional tests revealed that no spontaneous single-step zafirlukast-resistant mutants of S. mutans could be developed (data not shown). In future studies, it would be interesting to perform structure-activity studies to increase the antibacterial potency of zafirlukast. To our knowledge, this is the first study describing the activity of zafirlukast against multiple Gram-positive pathogens and P. gingivalis. Interestingly, a previous study demonstrated that zafirlukast exhibits antibacterial activity against various mycobacterial species (Pinault et al. 2013) . Zafirlukast inhibits growth of mycobacteria by binding the nucleoid-associated protein Lsr2, and thereby inhibiting complexation between Lsr2 and DNA. Since the bacteria tested in this study do not encode an Lsr2 homolog, we believe that the antibacterial mode of action of zafirlukast may be different form the mycobacterial mode of action. In an in vitro study, zafirlukast has also been reported to bind with DnaK, a molecular chaperone which plays a key role in maintaining protein homeostasis (Cesa et al. 2013) . Furthermore, previous studies have demonstrated the involvement of this protein in biofilm formation, as dnaK-deficient mutants have reduced biofilm-forming capacities (Arita-Morioka et al. 2015) . In future mode-of-action studies, it would thus be interesting to investigate if binding of zafirlukast to DnaK of P. gingivalis and S. mutans is responsible for the observed antibacterial effects.
Effect of zafirlukast against biofilms
In nature, bacteria are usually organized in biofilms, rendering them 10 to 1000 times less susceptible to antibacterial agents (Mah and O'Toole 2001) . Therefore, we investigated the ability of zafirlukast to inhibit biofilm formation and to target bacteria present within existing biofilms by determining MBIC and MBRC values, respectively (Table 1) . Zafirlukast effectively inhibited biofilm formation of the Gram-positive pathogens S. mutans, Staphylococcus epidermidis and S. aureus, and of P. gingivalis, and also reduced the viability of existing biofilms of these pathogens.
Activity of zafirlukast against biofilms grown on titanium disks
Biofilm tests described above were performed using polystyrene plates. This material is widely used in antibacterial assays as it enables rapid testing of large numbers of samples and promotes adherence of bacterial cells (Merrit, Hitchins and Brown 1999) . It is however not used in biomaterials. Titanium on the other hand is extensively used in the field of dental implants because of its excellent physical properties and biocompatibility (Grosgogeat, Reclaru and Lissac 1999) . Therefore, the effect of zafirlukast against biofilms of oral pathogens P. gingivalis and S. mutans formed on titanium disks was evaluated. Biofilm formation of both pathogens on titanium disks was significantly reduced at concentrations ≥12.5 μM for P. gingivalis (Fig. 1A) and at concentrations ≥25 μM for S. mutans (Fig. 1B) . In addition, the ability of the compound to eradicate existing biofilms of P. gingivalis and S. mutans formed on titanium disks was examined. Exposure of these biofilms to 50 μM zafirlukast reduced the viability of the biofilms of P. gingivalis and S. mutans by 99.9% and 98%, respectively ( Fig. 2A and B) . Strikingly, for S. mutans, the activity of zafirlukast is higher on existing biofilms than on biofilm formation. These results may indicate that zafirlukast exerts a specific effect against existing S. mutans biofilms on titanium, for example, by both attacking the biofilm matrix along with bactericidal activity. The activity of zafirlukast against biofilms formed on titanium surfaces was confirmed by fluorescence microscopy images by LIVE/DEAD staining, showing reduced numbers of green viable cells in the presence of zafirlukast (Figs 1 and  2 ). Of note, in nature, most biofilms consist of multiple species, thereby changing their physiological behaviors and pathogenesis (Guo, He and Shi 2014; Wang et al. 2015) . Therefore, in future experiments, the activity of zafirlukast against mixed biofilms will be investigated. Furthermore, in future studies, it would be of interest to examine the activity of zafirlukast against biofilms formed on dental surfaces such as acrylic denture, dental porcelain and hydroxyapatite.
Effect of zafirlukast on the viability of osteoblast-like cells
In addition to the initial establishment of osseointegration, maintenance of the osseointegrated state of installed implants is a crucial step in the successful prosthetic rehabilitation of patients by means of oral implants (Mavrogenis et al. 2009) . Bone homeostasis at the interface of the implants with the tissues is crucial, with the osteoblast (together with the osteoclast) being one of the key players. For that reason, we assessed whether zafirlukast is non-toxic for MG63 osteoblast-type cells (Fig. 3A) . We found that concentrations of zafirlukast that show antibacterial and antibiofilm activity do not compromise the growth potential of osteoblasts. These results were further confirmed by performing a LIVE/DEAD assay after incubating the cells with zafirlukast (50 μM) (Fig. 3B) . These results indicate that zafirlukast shows promise to be used in the management of dental implant-related infections, for example, as a locally applied antibiotic or as an antibiofilm coating for dental implants. However, further studies using relevant in vivo models will be required to support these treatment strategies.
CONCLUSION
Overall, our results reveal that zafirlukast exhibits antibacterial and antibiofilm activity against clinically relevant oral pathogens, including Porphyromonas gingivalis and Streptococcus mutans.
In addition, we demonstrate that zafirlukast exerts no toxicity on human osteoblasts. Since zafirlukast has a good oral bioavailability, it is likely that the compound can easily access the site of oral infections (Dekhuijzen and Koopmans 2002) . Furthermore, this compound is known to have relatively few side effects (Calhoun 1998) . Taking all these factors into account, we believe that zafirlukast has the potential to become an alternative agent for the prevention and treatment of peri-implantitis and other oral infections.
